• Subscribe
  • Register for free Content
  • Cart
  • Login
  • Browse by Topic
    • 13 Reasons Why
    • Abstinence
    • Acamprosate
    • Addiction
    • Addiction Treatment
    • Addyi
    • Adhansia XR
    • ADHD
    • Adherence
    • adolescents
    • Adult ADHD
    • Adverse Childhood Experiences (ACES)
    • Affordable Care Act (ACA)
    • Agitation
    • air pollution
    • Akathisia
    • Alcohol
    • Alcohol Use
    • Alcohol use disorder
    • Alcoholism
    • Alpha Agonists
    • Alternative treatments
    • Amantadine
    • amphetamine
    • Amphetamines
    • Anorexia Nervosa
    • Antidepressant Augmentation
    • Antidepressants
    • Antipsychotic
    • Antipsychotics
    • Anxiety
    • Anxiety Disorder
    • APA CE Post-Test
    • Aripiprazole
    • ArModafinil
    • Asenapine
    • Assessment
    • asthma
    • atamoxetine
    • attention
    • Attention Deficit Hyperactivity Disorder
    • Atypical Antipsychotics
    • Austedo
    • Autism
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder autism spectrum disorder
    • Behavior therapy
    • Behavioral addiction
    • Behavioral therapy
    • Behavioral treatment
    • Belsomra
    • Benzodiazepines
    • Beta-blockers
    • Billing
    • Bipolar Depression
    • Bipolar Disorder
    • Bipolar II
    • Board Certification
    • Borderline Personality Disorder
    • BPD
    • Brain Devices
    • Brief psychotherapy
    • Brief Strategic Family Therapy (BFST)
    • Bullying
    • Buprenorphine
    • Bupropion
    • C-Reactive Protein
    • Caffeine
    • CAM Treatments
    • Cannabidiol
    • Cannabis
    • Caplyta
    • Carbamazepine
    • Cardiovascular
    • Cariprazine
    • Chantix
    • Child and adolescent
    • Child Psychiatry
    • Child Psychiatry
    • children
    • Chokroverty
    • Citalopram
    • Clinical practice
    • Clozapine
    • CME Post-Test
    • Co-occurring disorders
    • Cocaine
    • Cognition
    • Cognitive Behavioral Therapy
    • Cognitive Decline
    • cognitive impact
    • Cognitive Rehabilitation Therapy (CRT)
    • Collaborative care
    • community trauma
    • Comorbidity
    • Complementary treatments
    • Complimentary treatments
    • Computer addiction
    • Computers in Psychiatric Practice
    • Conduct Disorder
    • Confidentiality
    • Connect
    • Connection
    • Connections
    • Contagion
    • Coronavirus
    • Cosmetic pharmacology
    • COVID-19
    • COVID19
    • Crime
    • Criminal behavior
    • Crisis intervention
    • Crocus Sativus
    • CRP
    • Cultural Competence
    • Culture
    • Cymbalta
    • Dayvigo
    • Delusional Disorder
    • Dementia
    • Deplin
    • Deprescribing
    • Depression
    • Depressive Disorder
    • Deutetrabenazine
    • Diagnosis
    • Diagnostic Testing
    • Disaster
    • Disparities
    • Diversity
    • Dopamine
    • DSM
    • Dual diagnosis
    • Duloxetine
    • Dyslexia
    • Dysregulation
    • E-Cigarettes
    • Eating Disorders
    • eCigarettes
    • ECT
    • Effexor
    • efficacy
    • electronic use
    • emergent suicidality
    • Emotional dysregulation
    • End of Life Care
    • Engagement
    • Escitalopram
    • Esketamine
    • eTNS
    • Exercise
    • Existing marijuana
    • expressed emotion
    • extended-release
    • Falls
    • Family Separation
    • FDA Warnings
    • Female hypoactive sexual desire disorder
    • Female Issues in Psychiatry
    • Fluoxetine
    • Folate
    • Folic Acid
    • Free Articles
    • gabapentin
    • GAD
    • Gender
    • Gender & Sexuality
    • Gender Diverse
    • Gender Dysphoria
    • Gender Identity
    • Generalized Anxiety Disorder
    • Generics
    • GeneSight
    • Genetic Testing
    • Genetics and Psychiatry
    • Geriatric Psychiatry
    • Ginkgo
    • Guanfacine
    • Hair loss
    • Harm reduction
    • Head Trauma
    • Health Apps
    • Heart health
    • Heart rate
    • Hepatitis
    • Heroin
    • HIPAA
    • Histamine
    • HIV
    • Hormone Replacement Therapy
    • Hypnotics
    • Hypomania
    • Incarceration
    • Inflammation
    • Ingrezza
    • Inpatient Psychiatry
    • inquiry
    • Insomnia
    • Insurance
    • Internet
    • Interpreter
    • Intervention
    • Irritability
    • Keppra
    • Ketamine
    • l-methylfolate
    • Laboratory Testing in Psychiatry
    • Lamictal
    • Lamotrigine
    • Language
    • Lavender
    • Learning & Developmental Disabilities
    • Legal issues
    • Lemborexant
    • Levetiracetam
    • LGBT
    • LGBTQ+
    • Life coaching
    • Life expectancy
    • Light and Dark Therapy
    • Light therapy
    • Lightbox
    • Literacy
    • Lithium
    • Longevity
    • Low libido
    • Lumateperone
    • Lurasidone
    • Lyrica
    • Management
    • Mania
    • MAOIs
    • Marijuana
    • Media
    • Medical Comorbidities
    • Medication
    • Medication adherence
    • Melatonin
    • Meta-analysis
    • Metabolic syndrome
    • Metformin
    • Methadone
    • methylfolate
    • methylphenidate
    • Micronutrients
    • Mind-Gut Connection
    • Mindfulness
    • Minority
    • Mirtazapine
    • Mixed Features
    • Modafinil
    • Mood Stabilizers
    • Mortality
    • Motivational Interviewing
    • Naloxone
    • Naltrexone
    • Narcolepsy
    • Natural Medications
    • natural treatments
    • Negative Symptoms
    • Netflix
    • Neurology
    • Neuroscience in Psychiatry
    • Neurotoxicity
    • New York
    • News of Note
    • Nightmares
    • Norepinephrine
    • Nortriptyline
    • Novel Medications
    • Nuedexta
    • Nuplazid
    • Nutrition
    • Nuvigil
    • Obesity
    • OCD
    • olanzapine
    • online therapy
    • Opioid epidemic
    • Opioid Use Disorder
    • Opioids
    • Oral Contraceptives
    • Orexin
    • Orthostasis
    • Outpatient
    • Overdose
    • Oxcarbazepine
    • Pain
    • pandemic
    • Panic Disorder
    • Parenting Strategies
    • Parkinson’s
    • Parkinson’s Disease
    • Paroxetine
    • Particulate matter
    • Patch
    • Patient relationship
    • pediatric
    • Perseveration
    • Perseverative Behavior
    • Personality Disorders
    • Pharmaceutical Industry
    • Pharmacology
    • Pharmacology Tips
    • Pharmacy
    • phonemic awareness
    • Phonics
    • Physician assisted suicide
    • PICOT
    • Pimozide
    • Pitolisant
    • Podcast
    • polypharmacy
    • Postpartum Depression
    • Potency
    • Practice Tools and Tips
    • Practice Tools and Tips
    • Pramipexole
    • Prazosin
    • Pregabalin
    • Pregnancy
    • prescribing patterns
    • Prescription costs
    • Prevention
    • Primary care
    • Prison
    • Prodrome
    • Prolonged exposure
    • Promotoras
    • Pronouns
    • Provigil
    • Prozac
    • pseudobulbar affect
    • Psychiatric interviewing
    • Psychological First Aide
    • Psychopharm Myths
    • Psychopharmacology
    • Psychopharmacology Tips
    • Psychosis
    • Psychotherapy
    • Psychotherapy
    • Psychotic Depression
    • Psychotropic medication
    • PTSD
    • Public health
    • Quetiapine
    • Randomized controlled trial
    • rapid naming
    • Reading
    • Reading disorder
    • Reading Disorders
    • Reading remediation
    • Red Cross
    • Registered Articles
    • Relationships
    • Remediation
    • Repetitive Behavior
    • Repetitive behaviors
    • Research
    • Research Update
    • Research Updates
    • retention
    • Retirement
    • Risk
    • Risk Management
    • Risperidone
    • Ritalin
    • rTMS
    • safety
    • Saffron
    • Saphris
    • Schizophrenia
    • School Refusal
    • Seasonal Affective Disorder
    • Secuado
    • Self-injury
    • Self-Regulation
    • Serotonin Specific Reuptake Inhibitors (SSRIs)
    • Sertraline
    • Sex Therapy
    • Sexual Dysfunction
    • Sexual Side Effects
    • Side Effects
    • Silexan
    • Skype
    • Sleep
    • Sleep Apnea
    • Sleep Disorders
    • Smoking Cessation
    • Smoking Cessation Agents
    • smoking cessations
    • Social Anxiety Disorder
    • social cohesion
    • Special populations
    • SSRIs
    • Stereotypical Behavior
    • steroids
    • Stigma
    • stimulant
    • Stimulants
    • structured literacy
    • Suboxone
    • Substance Abuse
    • Substance Abuse
    • Substance Use
    • Substance Use Disorder
    • Substance use disorders
    • Suicidality
    • Suicide
    • Suvorexant
    • Symptom Assessment
    • Symptom Management
    • Systematic review
    • Tardive dyskinesia
    • Technology
    • Teen
    • teens
    • Telehealth
    • Telemed
    • Telemedicine
    • Telepsychiatry
    • test cme quiz
    • TGD
    • Therapy during medication appointment
    • Therapy with Med Management
    • TMS
    • Tobacco
    • tobacco research
    • Tobacco use disorder
    • Toxic Stress
    • Transcranial Magnetic Stimulation
    • Transdermal
    • Transgender
    • Translator
    • Trauma
    • Trauma Informed Care
    • Traumatic Brain Injury (TBI)
    • Trazodone
    • treatment
    • treatment pediatric
    • Treatment planning
    • Treatment-Resistant Depression
    • Trigeminal Nerve Stimulation
    • Trintellix
    • Understanding Psychiatric Research
    • Valbenazine
    • Vaping
    • Varenicline
    • Venlafaxine
    • videogaming addiction
    • Vitamin B6
    • Vitamin D
    • Vitamin E
    • VMAT2 Inhibitors
    • Vortioxetine
    • Vyleesi
    • Wakix
    • Weed
    • Weight gain
    • Weight Loss Medications
    • Wellbutrin
    • Wilderness Therapy Programs
    • Withdrawal
    • Women's Issues in Psychiatry
    • Women’s Issues in Psychiatry
    • Working With Families
    • Youth
  • HOME
  • STORE
  • CME CENTER
  • Blog
  • Podcast
  • NEWSLETTERS
    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
  • Archive
  • Archive
  • Archive
  • The Carlat Psychiatry Report
  • How to Talk about Medication (September)
  • A New Way to Talk to Patients about Medication

A New Way to Talk to Patients about Medication

The Carlat Psychiatry Report, Volume 17, Number 9, September 2019
https://www.thecarlatreport.com/newsletter-issue/tcprv17n9/

From The Carlat Psychiatry Report, September 2019, How to Talk about Medication

Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Topics: Collaborative care | Medication adherence | Patient relationship | Psychiatric interviewing | Psychotherapy | Therapy with Med Management

Print Friendly, PDF & Email

Shawn Christopher Shea, MDShawn Christopher Shea, MD

Director of the Training Institute for Suicide Assessment and Clinical Interviewing. Internationally recognized innovator in the fields of clinical interviewing and suicide prevention and author of seven books, several of which are included in Doody’s Core List of the most important books in psychiatry and medicine.

Dr. Shea has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

TCPR: We all want to communicate better with patients, particularly around medications. You’ve lead workshops on this for several decades. Tell us about the model you developed out of that work.
Dr. Shea: The Medication Interest Model (MIM) is a set of over 100 interview techniques that create shared decision making regarding all disease states from psychiatric illnesses to diabetes, congestive heart failure and AIDS. The MIM techniques were created to help experienced clinicians maximize patient interest and follow-through with medications in their day-to-day practices. The model is designed for psychiatrists, as well as general medical providers and trainees—anyone who talks with patients about their medications. It addresses everything from creating motivation to uncovering side effects and collaboratively matching medication choice to the unique cultural needs of the patient.

The Medication Interest Model: Sample Questions

Opening up Discussion

  • “Do you feel that you are on too little, too much, or just the right amount of this medication?”
  • “Since the last time we met, what have you thought about the risperidone we started?”
  • “Do you have a medication in mind that you might want to try for your depression?”
  • “Do you know anyone who has taken lamotrigine? What did they think of it?”
  • “How do you think your spouse will feel about you starting an antidepressant?”

Engaging Motivation

  • “Is there anything that your OCD is causing you to not be able to do that you really wish you could do again?”
  • “If I had a magic pill—and I don’t—but if I did, and it could take away one of your symptoms, which is the one you most want help with?”
  • “What would you like this medication to do for you?”

When Interest in Medication is Low

  • “Well, we probably disagree about whether or not you have schizophrenia, but you know, people are entitled to their own opinions, and I respect yours.”
  • “I’m getting the feeling that you are just a bit hesitant to start duloxetine. Which is okay, but I just have a hunch here (well-timed pause) you’re not going to take this thing, are you?”
  • “Many patients tell me that it’s easy to forget to take their medications. In the weeks since we last met, how many doses do you think you might have missed, just roughly: 10 doses, 15 doses, 20 doses?”

Side Effect Inquiries

  • “Are you having any problems that you are wondering whether or not they might be a side effect?”
  • “Are any side effects interfering with your relationships?”
  • “Would you want to stay on this medication if we could get rid of your side effects by cutting your dose in half?”
  • “Is taking the medication inconvenient for you in any way?”
  • “It can be tough for anyone to pay for medications; how much of a burden do you think this will be for you and your family?”

Source: Adapted from Shea SC, The Medication Interest Model, 2018

TCPR: How do we need to shift our mindset to do this work?
Dr. Shea: Here’s a good place to start: If patients don’t want to take a particular medication, they probably have a logical reason for not doing so. They are not being resistant; they are actually making the decision that we ourselves would make if we believed what they believe. There are usually three beliefs that a person generally needs to have in order to stay on a medication.

TCPR: What are those?
Dr. Shea: The first is that there is something wrong, or else they wouldn’t need the medication. Second, they have to believe that a medication is a reasonable option, and third, that the pros of that medication outweigh the cons. We call this the “Choice Triad”, and it fits with most patients, just as it would for us. Occasionally there are patients that might have characterological problems and don’t take the medications because they are oppositional. But that is not what is going on with the vast majority of patients. It’s not defiance. They legitimately do not think this medication is appropriate for them. And sometimes they are right.

TCPR: How does the Choice Triad play out in psychiatric patients?
Dr. Shea: Take schizophrenia. Many people who are in their first psychotic break do not think that there is anything wrong with them. Well, none of us would take a medication if we didn’t believe that there was something wrong with us, especially if it causes side effects like tardive dyskinesia. When we understand that they are making a wise decision for what they believe to be true, it changes the interaction; the way it feels to be in the room with them. The problem is not the patient; the problem is that the patient has a belief that is different than our own.

TCPR: Sounds like you need to understand the patient’s beliefs first. How do you get to that?
Dr. Shea: Ask how they feel on their medication right now and just take it from there. Often, they barely have to answer because it comes through in their body language. If it seems they’re on a medication that they clearly love, I’d give it some real thought before recommending a change. Sometimes we assume, or are pressured by administration to think, that we need to do something different at the first meeting. But that’s not always the case. Sometimes the medication regimen a person is on is the best one for them, even if they’re not getting total relief (see box below for MIM sample questions).

TCPR: How do you approach side effects?
Dr. Shea: I’ll ask, “What does it mean to you that you get lightheaded? What impact does that have on your life?” I’m looking for their perception, their fears. That’s what causes people to stop their medications; not simply the side effects but their beliefs about them. If it was just about the severity, no one would take chemotherapeutic agents for cancer, but they do. For a teacher or an actor, a “simple” dry mouth may be viewed as job-threatening, and they may feel that they need to stop the antidepressant no matter how much relief from their depression it is providing. In contrast, a patient who is no longer sexually active may find serious sexual side effects to be of no concern whatsoever.

TCPR: Empathy sounds very important here.
Dr. Shea: Yes. It’s all too easy to minimize side-effects. One thing that’s helped me avoid that is the realization that side effects are actually a disease. They fit Webster’s definition: A disease is something that causes pathophysiologic changes in the body. So, when we cause side effects, we are giving the patient a disease. We’re asking people to swap diseases. Is the disease that I have worse than the disease that these medications are causing? They are also struggling with the financial costs of the medicine and its psychological toll. What does it say about me that I have to take this medication?

TCPR: Patients often lose interest in medications when they are on them for prevention. How do you work with that?
Dr. Shea: Let’s say a person with bipolar disorder is euthymic on a combination of lithium and Depakote, and they are thrilled. They truly believe that the medications have helped. But with the passage of years that patient might still have a very normal human question: “Do I still need these meds?” They’re unlikely to share that doubt with me unless I ask them to: “You’ve been doing really well on your lithium and your valproate for the past two years. Some of my patients have told me that they start to wonder at this point, ‘Do I actually need these medications?’ Sometimes, they even have thoughts like ‘Maybe I should stop them or lower the dose’, and I’m just curious, have you had any thoughts like that?”

TCPR: And if they intend to stop them?
Dr. Shea: After gently reviewing the pros of staying on the medication in a non-defensive fashion I might say: “You know, I will always tell you what I believe. My personal belief is that I really think you should stay on these medications. On the other hand, if you definitely are going to stop them, then I think we ought to do it together. It’s usually not wise to stop a medication suddenly. It is safer to taper off slowly, one at a time, and I’d be willing to do that with you.” It’s important that the patient understand I’m on their side. “I hope you are able to stay well off the Depakote. The less medication one needs the better. My fear is that the bipolar disorder will come back. Let’s hope it doesn’t. Let’s do this together and let’s agree that you will call me if you get any of your early warning signs of mania or depression.”

TCPR: When is it better to step in more actively and challenge the patient?
Dr. Shea: For that to work they need to understand your philosophy around medications first. I usually explain that in the initial meeting. Here is just one example of a MIM technique for doing this called Introducing Shared Expertise: “I’d like to make sure you’re comfortable with my approach to using medications, because you are the one who’s putting them in your body; not me. My own feeling about medications is that they can be invaluable and even save lives. But I’m aware they can also cause bad side effects. This is a shared journey and we are both experts. I view myself as an expert on medications and their side effects, but you are the only person that knows what you are feeling on them. If for any reason, you decide there is a problem with a medication, please tell me. I’ll always want to know. Don’t stop it immediately; call me and I’ll try to help you figure out what’s going on.” Another thing I’ll say is: “I view it as my responsibility to let you know whether a medication seems to be working. If I see a problem with it, I’m gonna tell you that I think we should stop the medication.” The message that I am a watchdog for problems with medications—not a pill-pusher—means an enormous amount to patients.

TCPR: You explain what can happen if patients stop their meds, but can that ever backfire? Like when fear is used to motivate?
Dr. Shea: Yes, in the MIM we teach that one has to be careful with fear. Humans usually can’t tolerate high amounts of fear for long periods of time. Their defense mechanisms may kick in and they will either deny it’s a problem or rationalize it away. It is important for a person to legitimately be aware of the risks of the disease, including death in some instances, but without causing a terror that can backfire. But there are exceptions. There are patients that actually respond well—and require—being frightened. Like a coach, the art is figuring out when to do that and when not to.

TCPR: How do you work with patients who feel—accurately or inaccurately—that they are sensitive to medications?
Dr. Shea: At some point in the first meeting, when the patient is telling me what meds they’re on, I might say, “You know I’m really curious, do you think you’re particularly sensitive to medications?” If they hesitate, they probably are sensitive, or think they are. Then I’ll ask for examples. And if I think their examples are just common, benign side effects like nausea on SSRIs, I don’t challenge them on that. In an initial encounter such a challenge may set back the alliance because if I challenge them I am essentially saying, “I don’t believe you; you’re wrong.” Not exactly a good way to start off a therapeutic alliance.

TCPR: Any techniques for sensitive patients?
Dr. Shea: After I start to write the prescription, I’ll stop, and the patient will notice that I’ve stopped. And I will look at them and say, “You know what, if it’s okay with you, I would like to start this at half the recommended starting dose. I want to let your body get a chance to see what this feels like. And if everything is okay, we can then start to raise it to help with your symptoms. At this tiny dose it might not even help, but I just think it is a smart way to start up with this medication because of your history with sensitivity to medications. Would that be all right with you, to start that low?” The patient may very well go home and tell their spouse, “That’s the first damn doctor that ever listened to me.”

TCPR: Thank you for your time Dr. Shea.


Editor’s note: Dr. Shea covers the MIM in more detail in The Medication Interest Model (Philadelphia, PA: Lippincott Williams & Wilkins; 2018). He has also written a version focused on psychiatric patients in the online supplement to Psychiatric Interviewing: The Art of Understanding, 3rd Edition (Toronto, ON Canada: Elsevier;2017).


 

To learn more, listen to our 9/9/19 podcast, “A New Way to Talk about Psych Meds” with Shawn Christopher Shea.

 

Podcast Special: “Top Psychopharm Myths”. Our 9/30 podcast features an expert interview with Nassir Ghaemi MD, who challenges many common practices in his new textbook, Clinical Psychopharmacology (Oxford University Press, 2019)

Share this page!
Subscribe
Register for free content

Register For Free Articles

Register to receive free email newsletters with concise, practical advice for busy clinicians. You will also have access to select article content on the website and you will receive notifications of new books and special discount offers.




Courses and Book CME
Psychiatry Practice Boosters, Third Edition (2021)
The Medication Fact Book for Psychiatric Practice, Fifth Edition (2020)
2021 Carlat Psychiatry Report Self-Assessment Course
2020 Carlat Psychiatry Report Self-Assessment Course
The Child Medication Fact Book for Psychiatric Practice (2018)
Issue Archives

2019

  • Depression (May)
  • Adult ADHD (November/December)
  • Mental Health Apps (October)
  • How to Talk about Medication (September)
  • Side Effects Part II (August)
  • Side Effects Part I (June/July)
  • Sleep (April)
  • Parenting, Pregnancy, and Prevention (March)
  • Dark and Light Therapy (February)
  • Deprescribing (January)

2018

  • Drug Metabolism (November/December)
  • Working With Transgender Patients (October)
  • Emergency Psychiatry (September)
  • Treatment-Resistant Depression (July/August)
  • Neurobiology (June)
  • Anxiety (May)
  • Neurofeedback (April)
  • Antipsychotics Update (March)
  • Working With Families (February)
  • Bipolar Disorder (January)

2017

  • PTSD (December)
  • Retirement (November)
  • Intellectual Disability (September/October)
  • Antidepressants (July/August)
  • Personality Disorders (June)
  • Dementia (May)
  • Cognitive Behavior Therapy Techniques (April)
  • Pharmacogenetics (March)
  • Treating Psychosis (February)
  • Adult ADHD (January)

2016

  • Complementary and Alternative Medicine in Psychiatry (November/December)
  • Side Effects (October)
  • Pain Management (September)
  • Medication in Pregnancy (July/August)
  • Psychoanalysis in Modern Psychiatry (June)
  • Correctional Psychiatry (May)
  • Antidepressant Roundup (April)
  • Burnout (March)
  • Private Practice (February)
  • Bipolar Disorder (January)

2015

  • Psychiatry and General Medicine (November/December)
  • Biomarkers in Psychiatry (May)
  • Telepsychiatry (October)
  • Sleep Disorders (September)
  • Interventional Psychiatry (July/August)
  • Eating Disorders (June)
  • Psychotherapy Updates (April)
  • Topics in Geriatric Psychiatry (March)
  • Antipsychotics Update (February)
  • Risk Management (January)

2014

  • Bipolar Disorder (November/December)
  • Pharmacogenetics (October)
  • Keeping up in Psychiatry (September)
  • Research in Psychiatry (July/August)
  • Marijuana (June)
  • Psychiatric Diagnosis (May)
  • Issues in Psychopharmacology (April)
  • Schizophrenia (March)
  • Women’s Psychiatry (February)
  • Ethics in Psychiatry (January)

2013

  • Military Psychiatry (December)
  • Depression (November)
  • Treatment of Dementia (October)
  • Anxiety Disorders (September)
  • Natural and Alternative Treatments in Psychiatry (July/August)
  • Autism Spectrum Disorder (June)
  • Practice Tips (May)
  • Substance Abuse (April)
  • Medicolegal Topics (March)
  • End of Life Care (February)
  • Antipsychotic Update (January)

2012

  • Screening Tools and Tips (December)
  • Medical Comorbidities (November)
  • Devices in Psychiatry (October)
  • Eating Disorders (September)
  • Bipolar Disorder (July/August)
  • Risk Management (June)
  • Antidepressant Roundup 2012 (May)
  • Gender and Sexuality (April)
  • Personality Disorders (March)
  • ADHD (February)
  • Natural Treatments in Psychiatry (January)

2011

  • Electronic Medical Records (December)
  • Insomnia (November)
  • Psychotherapy (October)
  • Alcoholism (September)
  • Anxiety Disorders (July/August)
  • Schizophrenia (June)
  • Managing Side Effects (May)
  • Antidepressant Roundup 2011 (April)
  • DSM-5 and Diagnostic Issues (March)
  • Drug-Drug Interactions (February)
  • Bipolar Disorder (January)

2010

  • Hospital Psychiatry (December)
  • Psychiatric Medication in Pregnancy (November)
  • Maintenance of Certification (October)
  • The Neuroscience of Psychotherapy (September)
  • Treatment of Depression (July/August)
  • Email and the Internet in Psychiatry (June)
  • Substance Abuse (May)
  • The Diagnosis and Treatment of Dementia (April)
  • Ethics in Psychiatry (March)
  • Natural Treatments in Psychiatry (February)
  • ADHD (January)

2009

  • Treating Schizophrenia (December)
  • Treatment for Anxiety Disorders (November)
  • The Latest on Antidepressants (October)
  • Topics in Neuropsychiatry (September)
  • The Interface of Medicine and Psychiatry (July/August)
  • Generic Medications in Psychiatry (June)
  • The Treatment of Eating Disorders (May)
  • Healthcare Policy and Psychiatry (April)
  • Antipsychotic Roundup 2009 (March)
  • Psychiatric Medication in Pregnancy and Lactation (February)
  • Transcranial Magnetic Stimulation (January)

2008

  • Treating Fibromyalgia and Pain in Psychiatry (December)
  • Issues in Child Psychiatry (November)
  • Improving Psychiatric Practice (October)
  • Treating Personality Disorders (September)
  • Bipolar Disorder (July/August)
  • Antipsychotic Roundup 2008 (June)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Neuropsychological Testing (May)
  • Psychiatric Medications: Effects and Side Effects (April)
  • Update on Substance Abuse (March)
  • Anticonvulsants in Psychiatry (February)
  • Brain Devices in Psychiatry (January)

2007

  • The Treatment of Insomnia (December)
  • Avoiding Malpractice in Psychiatry (November)
  • Update on Eating Disorders (October)
  • Complex Psychopharmacology (September)
  • Laboratory Testing in Psychiatry (August)
  • Psychotherapy in Psychiatry (July)
  • Posttraumatic Stress Disorder (June)
  • Topics in Geriatric Psychiatry 2007 (May)
  • Pregnancy and Menopause in Psychiatry (Apil)
  • Antipsychotic Roundup 2007 (March)
  • Understanding Psychiatric Research (February)
  • Antidepressant Round-up 2007 (January)

2006

  • Technology and Psychiatric Practice (December)
  • The Use of MAOIs (November)
  • Medication Treatment of Depression (January)
  • Seasonal Affective Disorder (October)
  • Treatment of ADHD (September)
  • Topics in Bipolar Disorder (August)
  • Neurotransmitters in Psychiatry (July)
  • Treating Substance Abuse (June)
  • The STAR*D Antidepressant Trial (May)
  • Natural Treatments in Psychiatry (April)
  • Medication Treatment of Anxiety (March)
  • Panic Disorder: Making Treatment Work (March)
  • Antipsychotic Roundup 2006 (February)
  • Antidepressant Roundup 2006 (January)

2005

  • Self-Help Books and Psychiatry (December)
  • Genetics and Psychiatry (November)
  • Pregnancy and Psychiatric Treatment (October)
  • Benzodiazepines and Hypnotics in Psychiatry (September)
  • Geriatric Psychiatry Update (August)
  • Chart Documentation in Psychiatry (July)
  • The Treatment of Bipolar Disorder (June)
  • Weight Loss and Smoking Cessation in Psychiatry (May)
  • Treating ADHD (April)
  • Drug Industry Influence in Psychiatry (March)
  • Atypical Antipsychotics 2005 (February)
  • Antidepressant Roundup 2005 (January)

2004

  • Sexual Dysfunction (December)
  • Suicide Prevention (November)
  • To Sleep, To Awake (October)
  • Women’s Issues in Psychiatry (September)
  • OCD: An Update (August)
  • Chronic Pain and Psychiatry (July)
  • Neuroimaging in Psychiatry (June)
  • Natural Medications in Psychiatry (May)
  • Posttraumatic Stress Disorder (April)
  • Treatment of Alcoholism (March)
  • Battle of the Atypicals (February)
  • Antidepressant Roundup, 2004 (January)

2003

  • Research Methods in Psychiatry (December)
  • Antidepressants in Children (November)
  • The Treatment of Dementia (October)
  • Bipolar Disorder, Part II: The Novel Anticonvulsants (September)
  • Bipolar Disorder: The Basics (August)
  • Drug-Drug Interactions in Psychiatry (July)
  • Managing Antidepressant Side Effects (June)
  • Antidepressants in Pregnancy and Lactation (May)
  • ADHD: Medication Options (April)
  • Panic Disorder: Making Treatment Work (March)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Medication Treatment of Depression (January)

2019

  • Autism in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (May/June/July/August)
  • Substance Use in Children and Adolescents (September/October)
  • Trauma in Children and Adolescents (March/April)
  • Anxiety in Children and Adolescents (January/February)

2018

  • Psychotropic Risks in Children and Adolescents (May/June)
  • ADHD in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (September/October)
  • Autism in Children and Adolescents (July/August)
  • Anxiety in Children and Adolescents (March/April)
  • Suicide in Children and Adolescents (January/February)

2017

  • Adolescents (November/December)
  • ADHD in Children and Adolescents (September/October)
  • Psychosis in Children and Adolescents (August)
  • PANDAS, PANS, and Related Disorders (June/July)
  • Marijuana in Children and Adolescents (May)
  • Tourette’s and Other Tic Disorders in Children and Adolescents (March/April)
  • Autism in Children and Adolescents (January/February)

2016

  • Gender Dysphoria in Children and Adolescents (November/December)
  • Technology Issues With Children and Adolescents (September/October)
  • Mood Dysregulation in Children and Adolescents (July/August)
  • Eating Disorders in Children and Adolescents (May/June)
  • Conduct Disorder in Children and Adolescents (April)
  • Sleep Disorders in Children and Adolescents (March)
  • ADHD in Children and Adolescents (January/February)

2015

  • Antidepressant Use in Children (November/December)
  • Foster Care and Child Psychiatry (September/October)
  • Autism (July/August)
  • Trauma (May/June)
  • Anxiety Disorders (April)
  • Schools and Psychiatry (March)
  • Emergency Psychiatry in Children (January/February)

2014

  • Antipsychotics in Children (December)
  • ADHD (November)
  • Gender and Sexuality (September/October)
  • Psychotic Symptoms (Summer)
  • Medication Side Effects (May)
  • Food and Mood (April)
  • Learning and Developmental Disabilities (February)

2013

  • Complex Practice Issues (December)
  • Diet and Nutrition (November)
  • Child Psychiatry in DSM-5 (August/September)
  • Medication Side Effects and Interactions (June/July)
  • Problematic Technology (March/April)
  • Autism Spectrum Disorders (January/February)

2012

  • Bipolar Disorder (December)
  • Substance Abuse (October/November)
  • Transitional Age Youth (July/August)
  • Rating Scales (May/June)
  • Eating Disorders (March/April)
  • Behavioral Disorders (February)

2011

  • Treatment of Anxiety Disorders (December)
  • Trauma (November)
  • Bullying and School Issues (October)
  • Hidden Medical Disorders (August)
  • OCD and Tic Disorders (June)
  • Suicide and Non-Suicidal Self Injury (April)
  • Sleep Disorders (March)
  • ADHD (January)

2010

  • Use of Antipsychotics in Children and Adolescents (December)
  • Learning and Developmental Disabilities (October)
  • Major Depression (September)
  • Treating Children and Families (July)
  • The Explosive Child (May)

2019

  • Dual Diagnosis in Addiction Medicine (May/June)
  • Medical Issues in Addiction Practice (November/December)
  • Alcohol Addiction (September/October)
  • Legal Issues in Addiction Medicine (July/August)
  • Traumatic Brain Injury and Addiction (March/April)
  • Board Certification in Addiction Medicine (January/February)

2018

  • Opioid Addiction (November/December)
  • Addiction in Older Adults (October)
  • Sleep Disorders and Addiction (September)
  • Adolescent Addiction (July/August)
  • Pain and Addiction (May/June)
  • Cannabis and Addiction (March/April)
  • Stigma and Addiction (January/February)

2017

  • Pregnancy and Addiction (November/December)
  • Detox (Sepember/October)
  • Dual Diagnosis (August)
  • Alternatives to 12-Step Programs (June/July)
  • Recovery (May)
  • Psychiatric Uses of Street Drugs (March/April)
  • Sex Addiction (January/February)

2016

  • Prescription Drug Monitoring Programs (PDMPs) (November/December)
  • Addiction in Health Care Professionals (September/October)
  • Dialectical Behavior Therapy in Addiction (August)
  • Motivational Interviewing (June/July)
  • Benzodiazepines (May)
  • Opioid Addiction (March/April)
  • Families and Substance Abuse (January/February)

2015

  • The Twelve Steps (November/December)
  • Designer Drugs (September/October)
  • Residential Treatment Programs Decoded (July/August)
  • Nicotine and E-Cigarettes (June)
  • Drug Screening (April/May)
  • Integrating Therapy and Medications for Alcoholism (March)
  • Detoxification Protocols (January/February)

2014

  • Behavioral Addictions (December)
  • Risk and Reimbursement (November)
  • Stimulant Abuse (September/October)
  • Self-Help Programs (June)
  • Opioid Addiction (May)
  • Coping with Bad Outcomes (March)
  • Change Management in Addiction Treatment (January/February)

2013

  • Cocaine Addiction (December)
  • Relapse Prevention (November)
  • Cannabis Addiction (August/September)
  • Addiction in DSM-5 (June/July)
Editor-in-Chief

Chris Aiken, MD

Dr. Aiken is the director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice.

Full Editorial Information

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Subscriptions
  • Books
  • Online Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Child Psychiatry Report

Contact

  • info@thecarlatreport.com
  • 866-348-9279
  • PO Box 626, Newburyport MA 01950

Follow Us

© 2021 Carlat Publishing, LLC and Affiliates, All Rights Reserved.

Please see our Privacy Policy and the Hardware/Software Requirements to view our website.

×